Dr. Ami V Desai
Claim this profileUniversity of Chicago Comprehensive Cancer Center
Expert in Neuroblastoma
Studies Tumors
21 reported clinical trials
45 drugs studied
About Ami V Desai
Education:
- Obtained MD from Robert Wood Johnson Medical School.
- Earned MSCE from the University of Pennsylvania.
Experience:
- Board-certified pediatrician specializing in pediatric hematology/oncology.
- Focus areas include solid tumors, sarcomas, neuroblastoma, and adolescent and young adult (AYA) cancer care.
- Research interests in pharmacology and developmental therapeutics for solid tumors.
- Lead investigator in multiple studies with publications in renowned journals.
- Practicing since 2013 and a member of several prestigious medical societies.
Area of expertise
1Neuroblastoma
Global LeaderMYC positive
Stage IV
ALK positive
2Tumors
SMARCB1 positive
Stage IV
NY-ESO-1 positive
Affiliated Hospitals
Clinical Trials Ami V Desai is currently running
Iobenguane (131-I) + Vorinostat
for Neuroblastoma
This trial tests a combination of a radioactive drug and a cancer-fighting pill in patients with a specific type of neuroblastoma that hasn't responded well to other treatments. The radioactive drug kills cancer cells, and the pill makes them more vulnerable to the drug.
Recruiting1 award Phase 23 criteria
Chemotherapy
for Wilms Tumor
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Recruiting1 award Phase 212 criteria
More about Ami V Desai
Clinical Trial Related4 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Ami V Desai has experience with
- Dinutuximab
- Cyclophosphamide
- Irinotecan
- Temozolomide
- 131I-MIBG
- Vorinostat
Breakdown of trials Ami V Desai has run
Neuroblastoma
Tumors
Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ami V Desai specialize in?
Ami V Desai focuses on Neuroblastoma and Tumors. In particular, much of their work with Neuroblastoma has involved MYC positive patients, or patients who are Stage IV.
Is Ami V Desai currently recruiting for clinical trials?
Yes, Ami V Desai is currently recruiting for 7 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Ami V Desai has studied deeply?
Yes, Ami V Desai has studied treatments such as Dinutuximab, Cyclophosphamide, Irinotecan.
What is the best way to schedule an appointment with Ami V Desai?
Apply for one of the trials that Ami V Desai is conducting.
What is the office address of Ami V Desai?
The office of Ami V Desai is located at: University of Chicago Comprehensive Cancer Center, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.